We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
To capitalise on emerging opportunities, domestic producers must ready themselves with large-scale, comprehensive clinical programmes which prove the safety of their biogenerics and efficacy in the treatment of the disease they target.